Allogene Therapeutics Inc

Allogene Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $51.7 million in cash and equivalents against total liabilities of $123.4 million, yielding a current ratio that suggests adequate short-term liquidity despite the absence of operating cash flow. The market capitalization stands at $401.5 million, trading at a price-to-book ratio of 1.37, which implies the market values the company’s tangible assets at a modest premium. The negative EV/EBITDA of -1.67 reflects the company’s pre-profitability status, where enterprise value is driven by equity rather than operating earnings.

Profitability metrics are deeply negative, consistent with a clinical-stage biotechnology firm. Return on equity is -65.25% and return on assets is -45.9%, indicating that the company is consuming capital to fund operations rather than generating returns. Operating income is -$209.3 million and net income is -$190.9 million for the latest period. Without cohort median data for direct comparison, these figures align with the industry norm for pre-revenue biotechs, where returns are negative until commercialization. The company has not yet achieved positive operating cash flow, with operating cash flow recorded at -$149.2 million, highlighting a reliance on external financing or existing cash reserves to sustain operations.

Revenue generation is currently non-existent, with reported revenue of $0.0. Consequently, there are no segment or geographic revenue mixes to analyze. The company’s business model is entirely dependent on the successful development and eventual commercialization of its therapeutic candidates. The absence of revenue concentration risk is offset by the total dependency on future clinical milestones and regulatory approvals for any future cash inflows.

Growth trajectory cannot be assessed through historical revenue trends due to the absence of revenue in the latest period and the lack of historical period data in the input. The company’s growth narrative is binary, hinging on clinical trial outcomes and regulatory decisions rather than organic sales growth. The share count remains stable at 229.4 million basic and diluted shares, suggesting no recent significant dilution events.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. However, the fundamental risk lies in the company’s burn rate relative to its cash position. With $51.7 million in cash and a recent operating cash outflow of $149.2 million, the company faces a significant runway challenge unless it secures additional capital or achieves milestone payments. The low dilution risk rating suggests that recent financing activities have not heavily impacted shareholder equity, but future capital raises may be necessary.

Recent observations include analyst estimates with a mean price target of $9.00, a median of $9.00, a high of $14.00, and a low of $4.00. The mean recommendation is 1.92, indicating a lean towards buy ratings, with 4 strong buys and 7 buys recorded. News events primarily reflect internal system reconciler activities rather than external corporate developments, suggesting a lack of recent public-facing news triggers.

Allogene maintains a strong liquidity position with a current ratio of 7.93, indicating ample short-term assets to cover liabilities.

The company carries zero long-term debt across all reported periods, eliminating interest expense and refinancing risks associated with leverage.

Operating losses improved by 23.4% year-over-year in the latest period, suggesting a potential stabilization in cost management efforts.

Free cash flow burn decreased by 26.9% year-over-year, indicating improved capital efficiency compared to the prior fiscal year.

Cash conversion metrics rank above the biotechnology cohort median, suggesting relatively efficient use of available capital resources.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing terms.

Net losses widened significantly in 2023 before stabilizing, reflecting persistent inability to achieve profitability over multiple years.

Operating income +29,3% YoY; Net income +28,7% YoY.

• ▍Operating income +29,3% YoY
• ▍Net income +28,7% YoY
• ▍Free cash flow +29,9% YoY

Revenue $0.00; Operating income +29,9% YoY.

• ▍Revenue $0.00
• ▍Operating income +29,9% YoY
• ▍Net income +35,2% YoY
• ▍Free cash flow +37,2% YoY

Revenue $0.00; Operating income +37,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +37,4% YoY
• ▍Net income +37,5% YoY
• ▍Free cash flow +39,3% YoY

Revenue $0.00; Operating income +20,5% YoY.

• ▍Revenue $0.00
• ▍Operating income +20,5% YoY
• ▍Net income +23,2% YoY
• ▍Free cash flow +23,6% YoY

Revenue $0.00; Operating income -$65.2M.

• ▍Revenue $0.00
• ▍Operating income -$65.2M

Revenue $0.00; Operating income -$60.5M.

• ▍Revenue $0.00
• ▍Operating income -$60.5M

Revenue $0.00; Operating income -$71.8M.

• ▍Revenue $0.00
• ▍Operating income -$71.8M

Revenue $0.00; Operating income -$71.4M.

• ▍Revenue $0.00
• ▍Operating income -$71.4M

Revenue $0.00, −100,0% YoY; Operating income +23,4% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +23,4% YoY
• ▍Net income +25,9% YoY
• ▍Free cash flow +26,9% YoY

Revenue $22.0k, −76,8% YoY; Operating income +16,6% YoY.

• ▍Revenue $22.0k, −76,8% YoY
• ▍Operating income +16,6% YoY
• ▍Net income +21,3% YoY
• ▍Free cash flow +22,2% YoY
• ▍Net margin -1170863.6%

Revenue $95.0k, −39,1% YoY; Operating income +2,3% YoY.

• ▍Revenue $95.0k, −39,1% YoY
• ▍Operating income +2,3% YoY
• ▍Net income +3,9% YoY
• ▍Free cash flow +5,0% YoY
• ▍Net margin -344489.5%

Revenue $156.0k, −99,9% YoY; Operating income −86,2% YoY.

• ▍Revenue $156.0k, −99,9% YoY
• ▍Operating income −86,2% YoY
• ▍Net income −87,0% YoY
• ▍Free cash flow −71,7% YoY
• ▍Net margin -218214.1%